Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
Launched by PROTHENA BIOSCIENCES LIMITED · Jun 4, 2014
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Idiopathic Parkinson's disease, Hoehn and Yahr 1-3
- • Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs
- • Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
- • Male subjects and their partners of childbearing potential must use contraception
- Exclusion Criteria:
- • Significant cardiac history
- • Abnormal MRI
- • Significant laboratory abnormalities
About Prothena Biosciences Limited
Prothena Biosciences Limited is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative diseases and other serious conditions. Leveraging its expertise in protein misfolding and aggregation, Prothena focuses on advancing innovative treatments targeting amyloid-related disorders, with a strong emphasis on precision medicine. Committed to scientific excellence and patient-centric approaches, the company collaborates with leading research institutions and industry partners to bring transformative therapies to market, aiming to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
New Haven, Connecticut, United States
Bingham Farms, Michigan, United States
Hallandale Beach, Florida, United States
Long Beach, California, United States
Orlando, Florida, United States
Boca Raton, Florida, United States
Portland, Oregon, United States
Patients applied
Trial Officials
Jay Soto
Study Director
Clinical Trials Prothena Biosciences Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials